Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I, randomized, double-blind, placebo-controlled, inter-individual, ascending dose, multi-site study to assess the safety, tolerability, and pharmacokinetics of AMY109 after a single subcutaneous administration in healthy volunteers and after multiple subcutaneous administrations in patients with endometriosis

Trial Profile

A phase I, randomized, double-blind, placebo-controlled, inter-individual, ascending dose, multi-site study to assess the safety, tolerability, and pharmacokinetics of AMY109 after a single subcutaneous administration in healthy volunteers and after multiple subcutaneous administrations in patients with endometriosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs AMY 109 (Primary)
  • Indications Endometriosis
  • Focus Adverse reactions
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 01 Jun 2018 Planned number of patients changed from 80 to 112.
    • 01 Jun 2018 Planned End Date changed from 1 Dec 2018 to 1 Oct 2020.
    • 06 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top